Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Genoscience Pharma
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
QuantuMDx Group Ltd. is developing handheld and portable low-cost diagnostic, genomic sequencing, and proteomic platforms that it thinks will promote the practice of personalized medicine in both developed and developing countries. The company aims to create devices that can provide results within minutes at point-of-care without the need for complex sample preparation processes, and that can integrate with mobile apps for ongoing patient support and education.
Biopharma financing totaled $3.7 billion in Q1 2012, $1 billion more than the previous quarter. A total of 22 M&As – with a potential value of $9.28 billion – were completed. Acquisitions of private biotechs structured with earn-outs were a highlight. About a quarter of the alliances involved Big Pharmas, with GlaxoSmithKline and Novartis taking the lead.
Funded in part by the Israeli government, BioLineRx believes it is about to score big with a cardiology drug being developed under FDA’s regulatory pathway for devices, as well as a schizophrenia candidate that could improve patients’ cognition.